Zymeworks EVP Adam Schayowitz sells $357,557 in shares

Zymeworks Inc. Executive Vice President Adam Schayowitz sold 13,832 shares of the company's stock on October 9, 2026, for $357,557. The sale was to cover tax withholding obligations and fees related to the vesting of restricted stock units. The shares traded between $25.85 and $25.88, with an average price of $25.85. Schayowitz's stock, currently at $25.79, showed a 42.8% return over the past year.

Simultaneously, he bought 37,037 more shares. Now holding 23,205 shares, Schayowitz also possesses 74,074 restricted stock units, with vesting set to begin in October 2026. Analysts view Zymeworks as undervalued, with a Strong Buy consensus and a predicted profitable year. The company's recent acquisition of Theravance Biopharma is anticipated to boost revenue streams.